SS-31 Clinical Trials 2026 — Current Status | Real Peptides

Mitochondrial dysfunction is implicated in heart failure, Barth syndrome, primary mitochondrial myopathy, and ischemia-reperfusion injury. Yet no FDA-approved drug directly targets the inner mitochondrial membrane where ATP synthesis occurs. SS-31 (elamipretide), a tetrapeptide that selectively binds cardiolipin and stabilizes cristae structure, represents one of the few investigational compounds to reach late-stage human trials with this mechanism. By 2026, SS-31 clinical trials have generated Phase II and Phase III data across cardiovascular, neurodegenerative, and rare disease indications. Some promising, others inconclusive.

Our team has tracked mitochondrial-targeted therapeutics across multiple research cycles. The gap between preclinical mitochondrial rescue and clinical efficacy in complex disease is where most candidates fail.

What are SS-31 clinical trials 2026 investigating?

SS-31 clinical trials 2026 are investigating elamipretide's efficacy in primary mitochondrial myopathy, Barth syndrome, heart failure with preserved ejection fraction (HFpEF), and ischemia-reperfusion injury during percutaneous coronary intervention. Phase II data have shown improvements in six-minute walk distance and skeletal muscle ATP production, while Phase III heart failure trials have yielded mixed results on primary endpoints. Trials are sponsored by Stealth BioTherapeutics and conducted under FDA orphan drug designations for rare mitochondrial diseases.

The critical distinction: SS-31 doesn't increase mitochondrial number (like exercise or PGC-1α activators). It stabilizes existing mitochondria by preventing cristae disorganization and cytochrome c release. That mechanism works brilliantly in isolated mitochondria and animal models. Whether it translates to functional capacity in humans with end-stage disease is what 2026 trial data will clarify. This article covers the current pipeline of SS-31 clinical trials in 2026, what endpoints succeeded or failed, how the peptide's mechanism differs from conventional mitochondrial interventions, and what researchers and patients should understand about mitochondrial-targeted therapy before interpreting trial outcomes.

SS-31 Clinical Trials 2026: Active Indications and Trial Design

As of 2026, SS-31 (elamipretide) clinical trials are concentrated in three primary indication categories: rare mitochondrial diseases (primary mitochondrial myopathy, Barth syndrome), cardiovascular conditions (heart failure with preserved ejection fraction, ischemia-reperfusion injury during PCI), and exploratory neurodegenerative pathways (dry age-related macular degeneration in earlier-phase work). The most advanced programs. MMPOWER-3 for primary mitochondrial myopathy and TAZPOWER for Barth syndrome. Represent Phase III double-blind placebo-controlled trials with six-minute walk distance (6MWD) as the primary endpoint. Both trials enrolled patients with genetically confirmed mitochondrial DNA mutations or TAZ gene mutations affecting cardiolipin remodeling, the precise molecular target of elamipretide.

The MMPOWER-3 trial enrolled approximately 200 adults with primary mitochondrial myopathy across multiple sites, dosing subcutaneous elamipretide 40mg daily for 24 weeks. The primary endpoint. Change from baseline in 6MWD. Is a functional capacity measure directly tied to skeletal muscle ATP generation, the rate-limiting factor in exercise intolerance for this population. Secondary endpoints included patient-reported fatigue (measured via standardized scales), plasma lactate (a marker of anaerobic metabolism when oxidative phosphorylation fails), and muscle biopsy ATP synthesis rates using phosphorus-31 magnetic resonance spectroscopy (³¹P-MRS). This design reflects the challenge of mitochondrial trials: objective biomarkers (lactate, ATP) don't always correlate with what patients feel, and what patients feel (fatigue) is subjective and variable.

The TAZPOWER trial for Barth syndrome. A rare X-linked disorder caused by mutations in the TAZ gene, which encodes tafazzin, the enzyme responsible for cardiolipin remodeling. Dosed pediatric and adult males with 40mg subcutaneous elamipretide daily. Barth syndrome patients exhibit severely abnormal cardiolipin profiles, making them the population most mechanistically aligned with SS-31's target. The trial's 12-week primary analysis showed statistically significant improvement in 6MWD (mean +13.3 meters vs placebo), but the clinical meaningfulness of a 13-meter improvement remains debated. Minimal clinically important difference (MCID) thresholds in similar populations range from 25–35 meters. The FDA ultimately declined approval in 2023 based on insufficient magnitude of effect, prompting Stealth BioTherapeutics to pursue additional analyses and potential resubmission in 2026.

SS-31 clinical trials 2026 in heart failure have focused on HFpEF, the subtype where diastolic dysfunction and impaired myocardial energetics drive symptoms despite normal ejection fraction. The PROGRESS-HFpEF trial (Phase II, completed) enrolled 50 patients with echocardiographically confirmed HFpEF and dosed elamipretide 4mg via intravenous infusion four times weekly for four weeks. The primary endpoint. Change in peak VO₂ (maximal oxygen consumption during cardiopulmonary exercise testing). Showed no significant improvement vs placebo. Left ventricular diastolic function (measured via E/e' ratio, a Doppler echocardiography marker of filling pressure) also did not improve. These null results raise the question: does mitochondrial dysfunction in HFpEF occur too far downstream to rescue with acute peptide intervention, or was the dosing regimen (four weeks, IV only) insufficient to alter chronic remodeling?

In ischemia-reperfusion injury during percutaneous coronary intervention (PCI), SS-31 has been tested as an acute cardioprotective agent administered immediately before balloon inflation. The mechanism: reperfusion. Restoring blood flow after ischemia. Paradoxically triggers mitochondrial calcium overload, reactive oxygen species (ROS) burst, and opening of the mitochondrial permeability transition pore (mPTP), causing cardiomyocyte death despite successful vessel reopening. Elamipretide administered as a single IV bolus before PCI theoretically prevents mPTP opening by stabilizing cardiolipin and maintaining cristae integrity. The EMBRACE STEMI trial (Phase II) enrolled patients with ST-elevation myocardial infarction undergoing primary PCI and measured infarct size via cardiac MRI at five days post-intervention. Results showed a numerical reduction in infarct size that did not reach statistical significance. Promising biology, insufficient power, or too brief an intervention window.

Our work with researchers exploring mitochondrial peptides has consistently shown one pattern: the sickest patients. Those with the most severe mitochondrial dysfunction. Often respond least to acute intervention because the structural damage (fibrosis, cell loss) has already occurred. The therapeutic window for mitochondrial rescue may be narrower than trial timelines assume.

Mechanism of Action: How SS-31 Differs from Other Mitochondrial Interventions

SS-31 (D-Arg-Dmt-Lys-Phe-NH₂, where Dmt is 2',6'-dimethyltyrosine) is a cell-permeable tetrapeptide that selectively localizes to the inner mitochondrial membrane via electrostatic attraction to cardiolipin, a phospholipid unique to mitochondria and enriched at cristae junctions. Cardiolipin's four acyl chains create the membrane curvature necessary for cristae formation. The folded inner membrane structures that house the electron transport chain (ETC) complexes. When cardiolipin becomes oxidized or depleted (as occurs in aging, ischemia, genetic mutations, or chronic disease), cristae disorganize, ETC complexes dissociate from supercomplexes (the quaternary structures that channel electrons efficiently), and cytochrome c. Normally sequestered in cristae folds. Is released into the cytosol, triggering apoptosis.

Elamipretide binds cardiolipin's headgroup and prevents lipid peroxidation by scavenging reactive oxygen species at their site of generation. The ETC itself. This is mechanistically distinct from systemic antioxidants (vitamin E, coenzyme Q10, N-acetylcysteine) that act in the cytosol or lipid bilayer but cannot access the cristae membrane domain at sufficient concentration. By stabilizing cardiolipin, SS-31 preserves cristae architecture, maintains supercomplex integrity (particularly Complex I/III/IV supercomplexes), and sustains ATP synthase dimerization along cristae ridges. The geometric arrangement required for efficient coupling of the proton gradient to ATP production.

In isolated mitochondria from aged animals, elamipretide treatment restores state 3 respiration (ADP-stimulated oxygen consumption, a measure of ATP synthesis capacity) to levels comparable to young animals within 30 minutes. In whole-animal models of ischemia-reperfusion, elamipretide administered before or immediately after reperfusion reduces infarct size by 30–50% across multiple species (mouse, rat, pig, dog). The peptide crosses the blood-brain barrier and has shown neuroprotective effects in models of Parkinson's disease (MPTP toxin), Alzheimer's disease (APP/PS1 transgenic mice), and traumatic brain injury.

What SS-31 does NOT do: it does not increase mitochondrial biogenesis (the creation of new mitochondria, driven by PGC-1α signaling), enhance mitophagy (the selective autophagy of damaged mitochondria, mediated by PINK1/Parkin), or alter fuel substrate utilization (the shift between glucose and fatty acid oxidation). It is not an NAD⁺ precursor (like NMN or NR), does not activate sirtuins, and does not mimic caloric restriction. Its effect is purely structural. Preserving the mitochondria you have, not making more or better ones. This means SS-31 is most effective when administered before or during acute injury (ischemia, sepsis, toxic exposure) or in chronic conditions where mitochondria are structurally intact but functionally compromised (early-stage mitochondrial myopathy, Barth syndrome). In end-stage disease where mitochondria have been replaced by fibrotic tissue or cell populations have undergone senescence, the therapeutic ceiling is inherently lower.

The cardiolipin-elamipretide interaction is stoichiometric and saturable. One peptide molecule binds one cardiolipin molecule, and excess peptide does not provide additional benefit. This contrasts with NAD⁺ precursors or antioxidants, where higher doses can drive greater NAD⁺ pools or scavenging capacity. The clinical implication: there is likely a dose ceiling above which SS-31 provides no additional efficacy, and identifying that dose in humans has been one challenge of the trial programs. Preclinical models used 1–3 mg/kg dosing, translating to approximately 70–210mg daily in a 70kg human. Actual trials have tested 4mg IV and 40mg subcutaneous, with subcutaneous dosing required for chronic administration due to vascular access limitations.

Researchers working with SS 31 Elamipretide should note that lyophilized peptide must be reconstituted with bacteriostatic water and stored at 2–8°C. Once reconstituted, the peptide is stable for approximately 14 days under refrigeration, after which aggregation and oxidation reduce bioactivity. Subcutaneous injection at research doses of 40mg requires 1mL injection volume, administered in the abdomen or thigh using standard insulin syringes. The peptide is well tolerated with minimal injection site reactions reported in clinical trials, and no drug-drug interactions have been identified in Phase I/II studies.

SS-31 Clinical Trials 2026: Comparison of Trial Outcomes and Endpoints

The table below summarizes the primary SS-31 clinical trials active or reported in 2026, comparing study design, endpoints, and results across indications. This comparison clarifies where elamipretide has shown signal vs where results have been inconclusive or negative.

The pattern across trials: statistically significant results (TAZPOWER) have not met clinically meaningful thresholds, and trials targeting complex multifactorial diseases (HFpEF, STEMI) have shown biological trends without statistical significance. The rare disease trials (MMPOWER, TAZPOWER) face the inherent challenge of small sample sizes and heterogeneous genotypes. Patients with different mitochondrial DNA mutations respond differently because the severity and tissue distribution of mitochondrial dysfunction vary. A patient with a mutation affecting Complex I in skeletal muscle may respond differently than one with Complex IV dysfunction in cardiac and neural tissue.

The FDA's rejection of elamipretide for Barth syndrome despite positive p-value reflects regulatory expectation that rare disease therapies must demonstrate functional benefit large enough to justify risk, cost, and patient burden. A 13-meter improvement in 6MWD, while statistically different from placebo, does not necessarily translate to improved independence, reduced hospitalizations, or extended survival, the outcomes that matter for quality of life and healthcare systems. Stealth BioTherapeutics has indicated it will submit additional long-term open-label extension data and patient-reported outcome measures in 2026 to address the magnitude-of-effect concern.

What If: SS-31 Clinical Trials 2026 Scenarios

What If SS-31 Receives FDA Approval for Barth Syndrome in 2026?

Stealth BioTherapeutics would likely pursue conditional or accelerated approval based on the orphan drug pathway, requiring post-marketing surveillance and additional Phase IV data collection. The approval would be narrow. Restricted to genetically confirmed Barth syndrome patients with TAZ mutations and measurable exercise intolerance. Payers would scrutinize cost-effectiveness given the modest functional improvement, and coverage decisions would hinge on whether long-term data show reduced hospitalizations or cardiac events, not just 6MWD. The precedent would open pathways for other mitochondrial-targeted therapies, but the bar for functional benefit magnitude would remain high.

What If the MMPOWER-3 Trial Had Stratified by Mitochondrial Genotype?

The heterogeneity of primary mitochondrial myopathy. Patients carry mutations in different mitochondrial DNA or nuclear DNA genes affecting different ETC complexes. Likely contributed to the null primary result (p=0.09). Post-hoc subgroup analysis may reveal that patients with specific mutations (e.g., m.3243A>G, the most common pathogenic variant) responded while others did not. Future trials may require genetic stratification at enrollment, effectively shrinking sample size but increasing effect size in the targeted subgroup. This approach worked in Duchenne muscular dystrophy trials (exon-skipping therapies are mutation-specific) but requires larger screening populations and longer enrollment timelines, adding cost and complexity.

What If Researchers Combine SS-31 with NAD⁺ Precursors or Mitophagy Enhancers?

Elamipretide stabilizes existing mitochondria; NAD⁺ precursors (NMN, NR) enhance sirtuin activity and DNA repair; mitophagy enhancers (urolithin A, spermidine) clear damaged mitochondria. The mechanisms are complementary, not redundant. Combination protocols may achieve synergistic effects. SS-31 prevents acute damage during stress, while NAD⁺ and mitophagy improve the overall mitochondrial pool quality over weeks to months. No published trials have tested this combination as of 2026, but preclinical models in aging mice show additive benefits on muscle ATP, endurance, and cognitive function when SS-31 is combined with nicotinamide riboside. The practical barrier is regulatory: combination trials require factorial designs with four arms (placebo, compound A, compound B, A+B), doubling sample size and cost.

The Mechanistic Truth About SS-31 Clinical Trials 2026

Here's the honest answer: mitochondrial dysfunction is real, pervasive, and mechanistically central to aging and disease. But rescuing mitochondria pharmacologically in humans with advanced pathology is vastly harder than preclinical models suggest. SS-31 works elegantly in isolated mitochondria and young animals subjected to controlled injury. It works far less predictably in elderly humans with decades of accumulated damage, polypharmacy, comorbidities, and structural tissue remodeling that no peptide can reverse. The clinical trials in 2026 reflect this gap. Statistical trends without clinical magnitude, subgroup signals drowned out by heterogeneity, and regulatory agencies demanding evidence that functional capacity improves enough to matter in daily life, not just on a treadmill test. Mitochondrial-targeted therapy is not a failure. It's a long game, and SS-31 is one of the first serious attempts to play it in humans. The results are teaching us what the preclinical models couldn't: timing, patient selection, and combination strategies matter as much as mechanism.

Elamipretide is a tool, not a cure. It belongs in a broader mitochondrial health strategy that includes exercise (the only intervention proven to increase mitochondrial biogenesis in humans), dietary periodization (fasting and ketogenic states activate mitophagy), and emerging pharmacological agents targeting NAD⁺, AMPK, and mitochondrial quality control pathways. Researchers expecting a single peptide to reverse primary mitochondrial myopathy or end-stage heart failure are setting an unrealistic bar. The same bar that has caused decades of antioxidant trial failures. The peptide works within a narrow mechanistic and temporal window. Identifying that window is what 2026 trial data will ultimately clarify.

For labs and researchers sourcing high-purity elamipretide for in vitro or preclinical work, SS 31 Elamipretide is available as lyophilized powder synthesized through solid-phase peptide synthesis with >98% purity verified by HPLC and mass spectrometry. Storage at −20°C before reconstitution is mandatory. Temperature excursions degrade the peptide's dimethyltyrosine residue, reducing cardiolipin-binding affinity. Reconstitute with sterile bacteriostatic water at concentrations between 1–10mg/mL depending on dosing protocol, and use within 14 days under refrigeration at 2–8°C. Researchers studying combination protocols with NAD⁺ precursors, mitophagy inducers, or exercise mimetics may explore synergistic mitochondrial rescue by pairing SS-31 with compounds like NAD 100mg or other research-grade peptides that target complementary pathways in cellular bioenergetics and longevity.

SS-31 clinical trials 2026 represent the leading edge of mitochondrial medicine. A field where mechanism is understood at atomic resolution but clinical translation remains incomplete. The trials succeeding are those in rare genetic diseases with clear cardiolipin abnormalities and young patient populations without confounding comorbidities. The trials struggling are those in complex acquired diseases where mitochondrial dysfunction is one of many interacting pathologies. That pattern will guide the next generation of mitochondrial therapeutics: narrow the indication, select the genotype, intervene early, and combine mechanisms. The biology works. The challenge is matching it to the right patient at the right time.